BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Ukrainian drones hit all three Baltic States − did Russia redirect them? - 2Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- 3Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- 4Why are NASA's Artemis astronauts wearing orange? What are they bringing to space? What to know about the preparation for their moon mission.
- 5Floods, Landslides Triggered By Heavy Rain In Afghanistan Leave 77 Dead In 10 days, Authorities Say
- Key Training: Picking a Significant for Monetary Achievement
- Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
- German mid-sized firms gloomy on outlook, survey finds
- Vote in favor of Your #1 sort of pie
- Here's how 'Bridgerton' fans can watch the first episode of Season 4 before its Netflix release later this month
- Scientists captured female sperm whales on video working together during a birth to protect the calf
- 'Stranger Things' star debunks claims of 'unseen footage' from Season 5, Volume 2 as backlash intensifies ahead of the series finale
- OPEC’s No. 2 Producer Burns Its Own Gas—Then Buys Iran’s
- 2024's Driving Clearing Robots: Master Suggestions and Surveys
